Fri, January 13, 2023
Thu, January 12, 2023
Wed, January 11, 2023
Tue, January 10, 2023
Mon, January 9, 2023

Andreas Argyrides Maintained (BMRN) at Hold with Increased Target to $83 on, Jan 11th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-83-on-jan-11th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andreas Argyrides of Wedbush, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Increased Target from $74 to $83 on, Jan 11th, 2023.

Andreas has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $95 on, Thursday, October 13th, 2022


These are the ratings of the 5 analyists that currently disagree with Andreas


  • Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Increased Target to $110 on, Monday, October 31st, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $113 on, Thursday, October 27th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022

Publication Contributing Sources